TBX20 promotes doxorubicin resistance in breast cancer cells through enhanced ABCC1 expression and inhibition of mitophagy
Shuai Nie, Dejian Liu, Jun Hu, Yu Gan, Liangliang Mi · 2026
Read TBX20 promotes doxorubicin resistance in breast cancer cells through enhanced ABCC1 expression and inhibition of mitophagy by Shuai Nie, Dejian Liu, Jun Hu, Yu Gan, Liangliang Mi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0353376.txt.
Description
Shuai Nie and four colleagues investigate why some breast cancers stop responding to a standard chemotherapy drug, in this 2026 PLOS ONE laboratory study. They focused on a gene-switching protein called TBX20, which public cancer data showed running high in breast tumours. In two breast cancer cell lines, raising TBX20 made cells grow, move, and invade more aggressively, and shrug off the drug doxorubicin.
The protein was found to switch on a pump gene that ejects the drug from cells. It also suppressed the cell's recycling of worn-out power stations, another survival trick. Blocking the pump or restoring recycling reversed the resistance in dishes — two candidate routes for making chemotherapy bite again.
Catalog record
| CREATOR | Shuai Nie, Dejian Liu, Jun Hu, Yu Gan, Liangliang Mi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41197 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |